The report from the Association for Accessible Medicines highlights the impact that accessible generic and biosimilar medicines have had on patients nationwide.
Labetalol HCl injection, 100 mg/20 ml and 200 mg/40 ml vial had a market value of approximately $6 million in the 12 months ended March 2021, according to IQVIA.